|
1
|
Rautava J, Luukkaa M, Heikinheimo K, Alin
J, Grenman R and Happonen RP: Squamous cell carcinomas arising from
different types of oral epithelia differ in their tumor and patient
characteristics and survival. Oral Oncol. 43:911–919. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Funk GF, Karnell LH, Robinson RA, Zhen WK,
Trask DK and Hoffman HT: Presentation, treatment, and outcome of
oral cavity cancer: a national cancer data base report. Head Neck.
24:165–180. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mehrotra R, Singh MK, Pandya S and Singh
M: The use of an oral brush biopsy without computer-assisted
anaylsis in the oral lesions: a study of 94 patients. Oral Surg
Oral Med Oral Pathol Oral Radiol Endod. 106:246–253. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lawoyin JO, Lawoyin DO and Aderinokun G:
Intra-oral squamous cell carcinoma in Ibadan: a review of 90 cases.
Afr J Med Med Sci. 26:187–188. 1997.PubMed/NCBI
|
|
5
|
Tomita M, Fujitani K and Aoyagi Y:
Synthesis of dl-cepharanthine. Tetrahedron Lett. 13:1201–1206.
1967. View Article : Google Scholar
|
|
6
|
Saito R, Tsuchiya S, Ishizuka T, Fueki N,
Ezawa K, Minato K, Nakano H, Takise A, Kurihara M and Fueki R:
Clinical effects of cepharanthine (Ceph.) on leukopenia by
chemotherapy in lung cancer patients. Nihon Gan Chiryo Gakkai Shi.
24:2587–2593. 1989.PubMed/NCBI
|
|
7
|
Ono M: Antitumor effect of cepharanthine:
activation of regional lymph node lymphocytes by intratumoral
administration. Clin Immunol. 19:1061–1064. 1987.
|
|
8
|
Morioka S, Ono M, Tanaka N and Orita K:
Synergistic activation of rat alveolar macrophages by cepharanthine
and OK-432. Gan To Kagaku Ryoho. 12:1470–1475. 1985.(In
Japanese).
|
|
9
|
Asaumi J, Kawasaki S, Nishikawa K, Kuroda
M and Hiraki Y: Effects of hyperthermia and cepharanthine on
adriamycin accumulation with change in extracellular pH. Int J
Hyperthermia. 11:27–35. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nishikawa K, Asaumi J, Kawasaki S, Kuroda
M, Takeda Y and Hiraki Y: Influence of cepharanthine on the
intracelluar accumulation of adriamycin in normal liver cells and
spleen cells of mice in vitro and in vivo. Anticancer Res.
17:3617–22. 1997.PubMed/NCBI
|
|
11
|
Hotta T, Tanimura H, Yamaue H, Iwahashi M,
Tani M, Tsunoda T, Tamai M, Noguchi K, Mizobata S, Arii K and
Terasawa H: Modulation of multidrug resistance by cepharanthine in
fresh human gastrointestinal tumor cells. Oncology. 54:153–157.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hotta T, Tanimura H, Yamaue H, Iwahashi M,
Tani M, Tsunoda T, Noguchi K, Mizobata S and Terasawa H:
Synergistic effects of tamoxifen and cepharanthine for
circumventing the multidrug resistance. Cancer Lett. 107:117–123.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Furusawa S, Wu J, Fujimura T, Nakano S,
Nemoto S, Takayanagi M, Sasaki K and Takayanagi Y: Cepharanthine
inhibits proliferation of cancer cells by inducing apoptosis.
Methods Find Exp Clin Pharmacol. 20:87–97. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harada K, Bando T, Yoshida H and Sato M:
Characteristics of antitumour activity of cepharanthin against a
human adenosquamous cell carcinoma cell line. Oral Oncol.
37:643–651. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Harada K, Supriatno, Yamamoto S, Kawaguchi
S, Yoshida H and Sato M: Cepharanthine exerts antitumor activity on
oral squamous cell carcinoma cell lines by induction of p27Kip1.
Anticancer Res. 23:1441–1448. 2003.PubMed/NCBI
|
|
16
|
Harada K, Ferdous T, Itashiki Y, Takii M,
Mano T, Mori Y and Ueyama Y: Cepharanthine inhibits angiogenesis
and tumorigenicity of human oral squamous cell carcinoma cells by
suppressing expression of vascular endothelial growth factor and
interleukin-8. Int J Oncol. 35:1025–1035. 2009. View Article : Google Scholar
|
|
17
|
Harada K, Ferdous T, Itashiki Y, Takii M,
Mano T, Mori Y and Ueyama Y: Effects of cepharanthine alone and in
combination with fluoropyrimidine anticancer agent, S-1, on tumor
growth of human oral squamous cell carcinoma xenografts in nude
mice. Anticancer Res. 29:1263–1270. 2009.
|
|
18
|
Burma S, Chen BPC and Chen DJ: Role of
non- homologous end joining (NHEJ) in maintaining genomic
integrity. DNA Repair (Amst). 5:1042–1048. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Buck D, Malivert L, de Chasseval R,
Barraud A, Fondaneche MC, Sanal O, Plebani A, Stephan JL, Hufnagel
M, le Deist F, Fischer A, Durandy A, de Villartay JP and Revy P:
Cernunnos, a novel nonhomologous end-joining factor, is mutated in
human immunodeficiency with microcephaly. Cell. 124:287–299. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ahnesorg P, Smith P and Jackson SP: XLF
interacts with the XRCC4-DNA ligase IV complex to promote DNA
nonhomologous end-joining. Cell. 124:301–313. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Callebaut I, Malivert L, Fischer A, et al:
Cernunnos interacts with the XRCC4 × DNA-ligase IV complex and is
homologous to the yeast nonhomologous end-joining factor Nej1. J
Biol Chem. 281:13857–13860. 2006.
|
|
22
|
O’Regan P, Wilson C, Townsend S and
Thacker J: XRCC2 is a nuclear RAD51-like protein required for
damage-dependent RAD51 focus formation without the need for ATP
binding. J Biol Chem. 276:22148–22153. 2001.PubMed/NCBI
|
|
23
|
Nakajima A, Yamamoto Y, Taura K, et al:
Beneficial effect of cepharanthine on overcoming drug-resistance of
hepatocellular carcinoma. Int J Oncol. 24:635–645. 2004.PubMed/NCBI
|
|
24
|
Ikeda R, Che XF, Yamaguchi T, et al:
Cepharanthine potently enhances the sensitivity of anticancer
agents in K562 cells. Cancer Sci. 96:372–376. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Biswas KK, Tancharoen S, Sarker KP,
Kawahara K, Hashiguchi T and Maruyama I: Cepharanthine triggers
apoptosis in a human hepatocellular carcinoma cell line (HuH-7)
through the activation of JNK1/2 and the downregulation of Akt.
FEBS Lett. 580:703–710. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kikukawa Y, Okuno Y, Tatetsu H, et al:
Induction of cell cycle arrest and apoptosis in myeloma cells by
cepharanthine, a biscoclaurine alkaloid. Int J Oncol. 33:807–814.
2008.PubMed/NCBI
|
